Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05076396 · ClinicalTrials.gov registry record · Phase 1

PM14 Administered Intravenously to Patients with Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by PharmaMar.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target
9
Study locations

NCT05076396 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by PharmaMar. The registered enrollment target is 150 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The trial reports 9 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05076396, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by PharmaMar.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
9
Study locations

Study Summary

Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new combination regimens of non-crossresistant agents with acceptable-and not completely overlapping-toxicities has been a major way to improve response rate and outcome of patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG PM14

Study Locations (9)

Madrid

  • Hospital General Universitario Gregorio Marañón - Madrid
  • Clinica Universidad de Navarra - Madrid
  • Hospital Universitario Fundación Jiménez Díaz - Madrid
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital Universitario Madrid Sanchinarro - Madrid

Massachusetts

  • Massachusetts General Hospital - Boston

Texas

  • MD Anderson Cancer Center - Houston

París

  • Gustave Roussy - Villejuif

Catalonia

  • Hospital Universitari Vall d'Hebron - Barcelona

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2017-09-06
Est. Completion 2025-08-13
Phase Phase 1

Sponsor

PharmaMar

32 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05076396

The ClinicalTrials.gov registry entry for NCT05076396 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PM14 is the first listed.

NCT05076396 reports 9 study locations spanning 5 distinct geographic areas - top geographies include Madrid, Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT05076396 about?

NCT05076396 is a clinical study titled "PM14 Administered Intravenously to Patients with Advanced Solid Tumors". Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new ...

What is the current status of trial NCT05076396?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2017-09-06. Estimated completion is 2025-08-13.

What conditions does trial NCT05076396 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05076396?

The interventions under investigation include: PM14 (DRUG).

Who is sponsoring clinical trial NCT05076396?

This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05076396 being conducted?

This trial has 9 study locations across Massachusetts, Texas, París, Catalonia, Madrid. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.